Drug Detail

Drug Name Everolimus
Trade Name Afinitor
Synonyms RAD001|Zortress
Drug Descriptions

Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov).

DrugClasses mTORC1 Inhibitor 8

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Therapy Description
CB-839 + Everolimus
Dasatinib + Everolimus
Exemestane + Everolimus
Pomalidomide + Everolimus + Dexamethasone
Everolimus + Erlotinib
Olaparib + Everolimus
BYL719 + Everolimus + Exemestane
Bicalutamide + Everolimus
Cisplatin + Everolimus + Paclitaxel
Enzalutamide + Everolimus
Ribociclib + Everolimus
Everolimus
Dexamethasone + Everolimus
Anakinra + Everolimus
Everolimus + Sorafenib
Everolimus + Letrozole
Cyclophosphamide + Etoposide + Everolimus + Nelarabine
Everolimus + Denosumab
Lapatinib + Capecitabine + Everolimus
Everolimus + Radiotherapy
Everolimus + Exemestane + Xentuzumab Xentuzumab (BI 836845) is a monoclonal antibody that binds to IGF-1 and IGF-2 and prevents binding to the IGF receptor (IGF-1R), resulting in decreased IGF-1R signaling (NCI Drug Dictionary).
Carboplatin + Doxil + Everolimus
Everolimus + Exemestane + LY2835219
Everolimus + Selumetinib
LEE011 + Everolimus + Exemestane
CH5132799 + Everolimus
MM-141 + Everolimus
Everolimus + Nelarabine
Everolimus + Gemcitabine
Everolimus + Fulvestrant + Neratinib
Everolimus + Metformin
Exemestane + Everolimus + Palbociclib
Everolimus + Sonidegib
Everolimus + Lapatinib
Niraparib + Everolimus
Everolimus + Hydroxychloroquine
AMG479 + Everolimus + Panitumumab
Abemaciclib + Everolimus
Eribulin + Everolimus
Everolimus + SCH772984
Everolimus + AMG479
Everolimus + PLX4720
Cyclophosphamide + Everolimus
IWR-1 + Everolimus
Octreotide acetate + Cixutumumab + Everolimus
Everolimus + Tacrolimus
Everolimus + Fosbretabulin
Everolimus + Lenvatinib
DTRMWXHS-12 + Everolimus + Pomalidomide
Trastuzumab + Everolimus
Dabrafenib + Everolimus + Trametinib
Bendamustine + Everolimus
Neratinib + Everolimus
Etoposide + Everolimus
Everolimus + Tamoxifen
Everolimus + Paclitaxel
Ribociclib + Everolimus + Letrozole
Everolimus + Sandostatin LAR Depot
Fulvestrant + Everolimus
Vemurafenib + Everolimus
Everolimus + Imatinib
XAV939 + Everolimus
Everolimus + GSK1120212
Ceritinib + Everolimus
Everolimus + H3B-5942
Everolimus + Itacitinib Afinitor (everolimus) binds to FKBP-12 and allosterically inhibits mTOR, leading to decreased mTORC1 signaling and potentially resulting in decreased tumor cell growth (PMID: 17766661, PMID: 28400999). Afinitor (everolimus) is FDA approved for use in neuroendocrine tumors of pancreatic, lung or gastrointestinal tract origin, advanced renal cell carcinoma, and in combination with Aromasin (exemestane) in hormone receptor-positive, HER2-negative breast cancer (FDA.gov).
BDA-366 + Everolimus
PDR001 + Everolimus
Everolimus + U0126
Everolimus + Pasireotide
Anastrozole + Everolimus
Fulvestrant + Everolimus + Anastrozole
Everolimus + Docetaxel
Everolimus + Vorolanib
Cisplatin + Everolimus + Gemcitabine
Binimetinib + Everolimus
Everolimus + Talazoparib
Panobinostat + Everolimus
ARN-509 + Everolimus
Everolimus + Bevacizumab
Bortezomib + Everolimus
DTRMWXHS-12 + Everolimus
Dexamethasone + Everolimus + Ribociclib
Bevacizumab + Doxorubicin + Everolimus
BKM120 + Everolimus
Everolimus + MK-1775
Everolimus + RX-0201
Everolimus + Pimasertib
BEZ235 + Everolimus
Trastuzumab + Everolimus + Vinorelbine
Everolimus + Toremifene
Everolimus + Letrozole + Trastuzumab
AEB071 + Everolimus
Everolimus + Sunitinib
everolimus + pazopanib
BYL719 + Everolimus
Everolimus + Letrozole + Metformin
Everolimus + Palbociclib
Everolimus + Paclitaxel + Carboplatin + Cetuximab
Everolimus + Octreotide
Vandetanib + Everolimus